Executive Director, HEOR and Access

Holly Guy

Holly is an expert in providing bespoke HEOR and access solutions to clients. She has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, including haematology, thrombosis, oncology, infectious diseases, and gastroenterology. She has been instrumental in more than 30 successful HTA submissions, including to NICE, SMC and AWMSG in the UK, andseveral countries across Europe. Having attended and represented pharmaceutical companies at NICE and AWMSG appraisalcommittee meetings. She also led the team that helped secure regulatory approval for treatment targeting advanced ovarian cancer, marking the first new product to reach the market in nearly 20 years.
Holly holds a Master's in Economic Evaluation in Healthcare (Distinction) from City University London and a First-Class degree in Engineering Mathematics from the University of Bristol.

Key facts

Leadership in HTA submissions
Led submissions to NICE, SMC, and AWMSG, with expertise in immune-oncology and survival analysis.
Systematic literature review and economic modelling expertise
Conducted over 40 literature reviews and 36 cost-effectiveness models across various disease areas.
Significant background in statistical analysis
Performed advanced survival analyses, contributing to key dossiers and health economic publications.
Experience in range of therapy areas:
  • Haematology, thrombosis
  • Oncology
  • Infectious diseases
  • Gastroenterology
  • Orphan/ultra-orphan conditions

Relevant service areas